Related Experiment Video
Updated: Jun 20, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Pharmacogenetics in cardiovascular antithrombotic therapy
Francisco Marín1, Rocío González-Conejero, Piera Capranzano
1Department of Cardiology, Hospital Universitario Virgen de Arrixaca, Murcia, Spain.
Insights
Individual genetic differences, known as pharmacogenetics, significantly impact how patients respond to antithrombotic drugs, affecting treatment efficacy and safety for thrombosis and stroke. Understanding these genetic variations is key to personalized antithrombotic therapy.
Area of Science:
- Pharmacology
- Genetics
- Cardiovascular Medicine
Background:
- Thrombosis is a primary cause of coronary artery disease and embolic stroke.
- Antithrombotic therapy is crucial but shows variable patient responses.
- Interindividual heterogeneity in treatment response necessitates further investigation.
Purpose of the Study:
- To review the role of genetic polymorphisms in individual responses to antithrombotic drugs.
- To explore how pharmacogenetics influences antithrombotic drug efficacy and safety.
- To highlight the importance of personalized medicine in antithrombotic treatment.
Main Methods:
- Review of existing literature on pharmacogenetics and antithrombotic therapy.
- Analysis of studies identifying gene variants affecting drug response.
- Synthesis of information on polymorphisms impacting drug disposition, metabolism, transporters, and targets.
Main Results:
- Specific gene polymorphisms significantly modulate patient responses to antithrombotic agents.
- Variations in drug metabolism and target genes explain a portion of treatment heterogeneity.
- Pharmacogenetic factors influence both the efficacy and safety profiles of antithrombotic drugs.
Conclusions:
- Pharmacogenetics plays a critical role in interindividual variability of antithrombotic drug response.
- Identifying relevant polymorphisms can optimize antithrombotic therapy selection and dosing.
- Personalized pharmacogenetic approaches promise improved outcomes in managing thrombotic conditions.
Abstract:
Thrombosis is the most important underlying mechanism of coronary artery disease and embolic stroke. Hence, antithrombotic therapy is widely used in these scenarios. However, not all patients achieve the same degree of benefit from antithrombotic agents, and a considerable number of treated patients will continue to experience a new thrombotic event. Such lack of clinical benefit may be related to a wide variability of responses to antithrombotic treatment among individuals (i.e., interindividual heterogeneity). Several factors have been identified in this interindividual heterogeneity in response to antithrombotic treatment. Pharmacogenetics has emerged as a field that identifies specific gene variants able to explain the variability in patient response to a given drug. Polymorphisms affecting the disposition, metabolism, transporters, or targets of a drug all can be implicated in the modification of an individual's antithrombotic drug response and therefore the safety and efficacy of the aforementioned drug. The present paper reviews the modulating role of different polymorphisms on individuals' responses to antithrombotic drugs commonly used in clinical practice.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Principles of Pharmacogenetics: Types of Genetic Variants
